120511-73-1
Product Name:
Anastrozole
Formula:
C17H19N5
Synonyms:
Anastrozole;Arimidex;2;2"-[5-(1H-1;2;4-Triazol-1-ylmethyl)-1;3-Phenylene]bis(2-methyl-propiononitrile;a,a,a′,a′-Tetramethyl-5-(1H-1,2,4-triazol-1-ylmethyl)-1,3-benzenediacetonitrile
Inquiry
CHEMICAL AND PHYSICAL PROPERTIES
Physical Description | Solid |
---|---|
Color/Form | Crystals from ethyl acetate/cyclohexane |
Melting Point | 81-82 °C |
Solubility | 0.53 mg/mL |
LogP | 1.58 |
Dissociation Constants | 1.4 |
SAFETY INFORMATION
Signal word | Danger |
---|---|
Pictogram(s) |
Exclamation Mark Irritant GHS07 Health Hazard GHS08 |
GHS Hazard Statements |
H302:Acute toxicity,oral |
Precautionary Statement Codes |
P202:Do not handle until all safety precautions have been read and understood. P264:Wash hands thoroughly after handling. P264:Wash skin thouroughly after handling. P270:Do not eat, drink or smoke when using this product. P280:Wear protective gloves/protective clothing/eye protection/face protection. P301+P312:IF SWALLOWED: call a POISON CENTER or doctor/physician IF you feel unwell. P308+P313:IF exposed or concerned: Get medical advice/attention. |
COMPUTED DESCRIPTORS
Molecular Weight | 293.4 g/mol |
---|---|
XLogP3 | 2.1 |
Hydrogen Bond Donor Count | 0 |
Hydrogen Bond Acceptor Count | 4 |
Rotatable Bond Count | 4 |
Exact Mass | 293.16404563 g/mol |
Monoisotopic Mass | 293.16404563 g/mol |
Topological Polar Surface Area | 78.3 Ų |
Heavy Atom Count | 22 |
Formal Charge | 0 |
Complexity | 456 |
Isotope Atom Count | 0 |
Defined Atom Stereocenter Count | 0 |
Undefined Atom Stereocenter Count | 0 |
Defined Bond Stereocenter Count | 0 |
Undefined Bond Stereocenter Count | 0 |
Covalently-Bonded Unit Count | 1 |
Compound Is Canonicalized | Yes |
PRODUCT INTRODUCTION
description
Anastrozole is a 1,2,4-triazole compound having a 3,5-bis(2-cyano-2-propyl)benzyl group at the 1-position. It has a role as an antineoplastic agent and an EC 1.14.14.14 (aromatase) inhibitor. It is a member of triazoles and a nitrile. Anastrozole is used for the treatment of advanced breast cancer in post-menopausal women.